<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03247868</url>
  </required_header>
  <id_info>
    <org_study_id>SPRIntFdG</org_study_id>
    <nct_id>NCT03247868</nct_id>
  </id_info>
  <brief_title>A Multimodal Approach to Cervical Dystonia Treatment With Association of Botulinum Toxin and Motor Learning Techniques</brief_title>
  <acronym>SPRInt</acronym>
  <official_title>Multimodal Treatment of Cervical Dystonia With Botulinum Toxin Injections Associated With a Sensory-motor Perceptive Rehabilitation Integrated Approach (SPRInt) Based on Motor Learning Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Don Carlo Gnocchi Onlus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of this study protocol is to describe, using a longitudinal study, a multimodal
      approach of treatment of cervical dystonia with botulinum toxin (BoNTA) and a new
      rehabilitation protocol named SPRInt (Sensory-motor perceptive rehabilitation integrated)
      approach based on motor learning techniques and spatial rehabilitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Longitudinal study utilizing a multimodal treatment protocol developing in six months time:

      Phase 1 : BoNTA injections localized in dystonic cervical muscles with EMG/US guides
      performed after polygraphy and kinematic analysis of cervical region Times: T0: pre
      treatment; T1: 6 weeks after T0 considered BoNTA pharmacological peak effect; T2: 12 weeks
      after T0 considered from guidelines and pharmaceutical data sheet the lowest BoNTA effect.

      Phase 2: BoNTA performed in the same way of Phase 1 associated to SPRInt protocol Times: T2:
      before combination of BoNTA and rehabilitation treatment (18 sessions of 45 minutes three
      times a week); T3: 6 weeks after T2 considered BoNTA pharmacological peak effect and the end
      of SPRInt protocol; T4: 12 weeks after T2 considered from guidelines and pharmaceutical data
      sheet the lowest BoNTA effect and follow up of SPRInt-consolidation.

      The SPRInt approach aims are to improve body perception, posture and movement quality and to
      restore body axis by using specific sensory feedbacks, both intrinsic (IFB) and extrinsic
      (EFB), and motor exercises (ME) with specific rhythmic temporal structure.The ME can be
      focused on different body parts (eyes, head, neck, trunk, arm) and involve different spatial
      planes (frontal, sagittal, horizontal, multiplanar).

      The exercises can be performed with eyes closed and with an external passive motor leading in
      order to improve proprioception and facilitate sensory integration by excluding visual or
      verbal information that can be misleading for the patient. The ability to perceive and
      integrate intrinsic feedback is the fundamental element to create mental image that define
      body scheme and motor behaviour.

      The extrinsic feedback can be continuous or discontinuous (on-off timing) and gives the
      patient information about the performance or result by positive or negative reinforcement;
      this process can be important to motivate and empower the patient in reaching new skills.

      The final goal for the patient is to reinforce and retain the informations collected with
      working memory and then stored with the consolidation process which ends in learning new
      skills (ie rescue postural axis) and improving motor tasks (ie move the head in the opposite
      position).

      At each time point these test are performed:

        -  CLINICAL SCALES i. Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)

             1. Severity

             2. Disability

             3. Pain ii. Quality of life iii. Depression Beck Scale iv. Zung Self Rating Anxiety
                Scale v. Rey Test to test visuo spatial abilities

        -  MOVEMENT ANALYSIS and KINEMATIC AND EMG MAPPING of cervical region ( head and neck)

        -  FUNCTIONAL MAGNETIC RESONANCE BRAIN STUDY to perform brain measurements of functional
           connectivity (resting state-Default Mode Network), morphometry (volume, area, cortical
           thickness, cortical curvature, node degree) and tractography.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 16, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dystonia phenomenology improvement</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>a clinical assessment of dystonia will be conducted at each study visit using TWSTRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>a clinical assessment of dystonia severity will be conducted at each study visit using quality of life scale (EQ5D5L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain plasticity</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>study of functional connectivity using functional magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depression</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>depression scale (BECK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>anxiety scale (ZUNG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural grey matter plasticity</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>brain study of morphometry using functional magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>structural white matter plasticity</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>tractography of brain areas using functional magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinematic assessment of dystonia severity</measure>
    <time_frame>every six weeks during six months time</time_frame>
    <description>visit with optoelectronic system</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Dystonia,Primary</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin+SPRInt protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Botulinum Toxin+SPRInt</intervention_name>
    <description>Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)</description>
    <arm_group_label>Botulinum toxin+SPRInt protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than 18 yo

          -  diagnosis of idiopathic cervical dystonia

          -  disease duration more than 6 months

        Exclusion Criteria:

          -  diagnosis of secondary dystonia on previously performed neuroimaging data (ie
             structural lesion of cervical spine, vascular or traumatic brain injuries)

          -  history of neuroleptic drug treatment (antidopaminergic drugs)

          -  associated neurological illness

          -  botulinum toxin treatment in the 3 previous months before recruitment

          -  head tremor without dystonic posturing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Castagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Fondazione Don Gnocchi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Castagna, MD</last_name>
    <phone>+39 02 40308075</phone>
    <email>acastagna@dongnocchi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Fondazione Don Gnocchi</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Castagna, MD</last_name>
      <phone>+3902 40308075</phone>
      <email>acastagna@dongnocchi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15;28(7):863-73. doi: 10.1002/mds.25475. Epub 2013 May 6. Review.</citation>
    <PMID>23649720</PMID>
  </reference>
  <reference>
    <citation>Boccagni C, Carpaneto J, Micera S, Bagnato S, Galardi G. Motion analysis in cervical dystonia. Neurol Sci. 2008 Dec;29(6):375-81. doi: 10.1007/s10072-008-1033-z. Epub 2008 Nov 29.</citation>
    <PMID>19043661</PMID>
  </reference>
  <reference>
    <citation>Walter U, Dressler D. Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives. Expert Rev Neurother. 2014 Aug;14(8):923-36. doi: 10.1586/14737175.2014.936387. Epub 2014 Jul 21. Review.</citation>
    <PMID>25046267</PMID>
  </reference>
  <reference>
    <citation>Prudente CN, Hess EJ, Jinnah HA. Dystonia as a network disorder: what is the role of the cerebellum? Neuroscience. 2014 Feb 28;260:23-35. doi: 10.1016/j.neuroscience.2013.11.062. Epub 2013 Dec 11. Review.</citation>
    <PMID>24333801</PMID>
  </reference>
  <reference>
    <citation>Delnooz CC, Pasman JW, van de Warrenburg BP. Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia. Neurobiol Dis. 2015 Jan;73:327-33. doi: 10.1016/j.nbd.2014.10.013. Epub 2014 Oct 28.</citation>
    <PMID>25447226</PMID>
  </reference>
  <reference>
    <citation>Delnooz CC, Pasman JW, Beckmann CF, van de Warrenburg BP. Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin. PLoS One. 2013 May 1;8(5):e62877. doi: 10.1371/journal.pone.0062877. Print 2013.</citation>
    <PMID>23650536</PMID>
  </reference>
  <reference>
    <citation>De Pauw J, Van der Velden K, Meirte J, Van Daele U, Truijen S, Cras P, Mercelis R, De Hertogh W. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol. 2014 Oct;261(10):1857-65. doi: 10.1007/s00415-013-7220-8. Epub 2014 Jan 12. Review.</citation>
    <PMID>24413637</PMID>
  </reference>
  <reference>
    <citation>van den Dool J, Visser B, Koelman JH, Engelbert RH, Tijssen MA. Cervical dystonia: effectiveness of a standardized physical therapy program; study design and protocol of a single blind randomized controlled trial. BMC Neurol. 2013 Jul 15;13:85. doi: 10.1186/1471-2377-13-85.</citation>
    <PMID>23855591</PMID>
  </reference>
  <reference>
    <citation>Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.</citation>
    <PMID>27164716</PMID>
  </reference>
  <reference>
    <citation>Currà A, Trompetto C, Abbruzzese G, Berardelli A. Central effects of botulinum toxin type A: evidence and supposition. Mov Disord. 2004 Mar;19 Suppl 8:S60-4. Review.</citation>
    <PMID>15027056</PMID>
  </reference>
  <reference>
    <citation>Kitago T, Krakauer JW. Motor learning principles for neurorehabilitation. Handb Clin Neurol. 2013;110:93-103. doi: 10.1016/B978-0-444-52901-5.00008-3. Review.</citation>
    <PMID>23312633</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

